iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.
Basic Details
Issuer Blackrock
Fund NameiShares Nasdaq Biotechnology ETF
Tax ClassificationRegulated Investment Company
SymbolNASDAQ:IBB
Inception Date2/5/2001
Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason
WebN/A
PhoneN/A
Fund Focus
Asset ClassEquity
BenchmarkNASDAQ Biotechnology TR USD
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America
Fund Statistics
Assets Under Management$8.90 billion
Average Daily Volume$2.74 million
Discount/Premium-1.41%
ETF Expenses
Management Fee0.47%
Other Expenses0.00%
Total Expenses0.47%
Fee Waiver0.00%
Net Expenses0.47%
Administrator, Advisor and Custodian
AdministratorState Street Bank and Trust Company
AdvisorBlackRock Fund Advisors
CustodianState Street Bank and Trust Company
DistributorBlackRock Investments, LLC
Transfer AgentState Street Bank and Trust Company
Trustee
Lead Market MakerVirtu Financial
iShares NASDAQ Biotechnology Index (NASDAQ:IBB) Frequently Asked Questions
What is iShares NASDAQ Biotechnology Index's stock symbol?
iShares NASDAQ Biotechnology Index trades on the NASDAQ under the ticker symbol "IBB."
How often does iShares NASDAQ Biotechnology Index pay dividends? What is the dividend yield for iShares NASDAQ Biotechnology Index?
iShares NASDAQ Biotechnology Index announced a quarterly dividend on Tuesday, June 26th. Stockholders of record on Wednesday, June 27th will be given a dividend of $0.1561 per share on Monday, July 2nd. This represents a $0.62 dividend on an annualized basis and a dividend yield of 0.53%. The ex-dividend date of this dividend is Tuesday, June 26th. This is an increase from iShares NASDAQ Biotechnology Index's previous quarterly dividend of $0.13. View iShares NASDAQ Biotechnology Index's Dividend History.
When did iShares NASDAQ Biotechnology Index's stock split? How did iShares NASDAQ Biotechnology Index's stock split work?
iShares NASDAQ Biotechnology Index's stock split before market open on Friday, December 1st 2017. The 3-1 split was announced on Tuesday, November 7th 2017. The newly created shares were distributed to shareholders after the closing bell on Thursday, November 30th 2017. An investor that had 100 shares of iShares NASDAQ Biotechnology Index stock prior to the split would have 300 shares after the split.
What is the consensus analysts' recommendation for iShares NASDAQ Biotechnology Index?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for iShares NASDAQ Biotechnology Index in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Who are some of iShares NASDAQ Biotechnology Index's key competitors?
Some companies that are related to iShares NASDAQ Biotechnology Index include DNP Select Income Fund Inc. Common Stock (DNP), Nuveen Municipal Value Fund (NUV), Adams Diversified Equity Fund (ADX), Tri-Continental (TY), Gabelli Equity Trust (GAB), Tortoise Energy Infrastructure (TYG), PIMCO Corporate&Income Opportunity Fund (PTY), Royce Value Trust (RVT), Liberty All-Star Equity Fund (USA), Hercules Capital (HTGC), Apollo Investment (AINV), PIMCO High Income Fund (PHK), Boulder Growth & Income Fund Inc common stock (BIF), AllianceBernstein Global Hgh Incm Fd (AWF) and General American Investors (GAM).
Who are iShares NASDAQ Biotechnology Index's key executives?
iShares NASDAQ Biotechnology Index's management team includes the folowing people:
- George G. C. Parker Ph.D., Independent Chairman of the Board of Trustees
- Michael Arthur Latham, President, Trustee
- Jack Gee, Chief Financial Officer, Treasurer
- Geoffrey D. Flynn, Chief Operating Officer, Executive Vice President
- , Bio & Compensation -
- Amy Schioldager, Executive Vice President
- Ira P. Shapiro, Vice President, Chief Legal Officer
- Matt Tucker, Vice President
- , Bio & Compensation -
- Eilleen M. Clavere, Secretary
- Cecilia H. Herbert, Independent Trustee
- Charles A. Hurty, Independent Trustee
Has iShares NASDAQ Biotechnology Index been receiving favorable news coverage?
Media stories about IBB stock have been trending somewhat positive on Tuesday, Accern Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. iShares NASDAQ Biotechnology Index earned a media sentiment score of 0.11 on Accern's scale. They also assigned press coverage about the financial services provider an impact score of 44.82 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are iShares NASDAQ Biotechnology Index's major shareholders?
iShares NASDAQ Biotechnology Index's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Bank of Montreal Can (0.36%), Avondale Wealth Management (0.15%), Vigilant Capital Management LLC (0.12%), Private Capital Advisors Inc. (0.10%), Crescent Grove Advisors LLC (0.09%) and Neville Rodie & Shaw Inc. (0.08%). View Institutional Ownership Trends for iShares NASDAQ Biotechnology Index.
Which institutional investors are selling iShares NASDAQ Biotechnology Index stock?
IBB stock was sold by a variety of institutional investors in the last quarter, including Private Capital Advisors Inc., Avondale Wealth Management, Crescent Grove Advisors LLC, Winfield Associates Inc., Vigilant Capital Management LLC, Neville Rodie & Shaw Inc., Quattro Financial Advisors LLC and Howard Capital Management Inc.. View Insider Buying and Selling for iShares NASDAQ Biotechnology Index.
Which institutional investors are buying iShares NASDAQ Biotechnology Index stock?
IBB stock was purchased by a variety of institutional investors in the last quarter, including Macguire Cheswick & Tuttle Investment Counsel LLC, Investment House LLC, Bank of Montreal Can, Personal Resources Investment & Strategic Management Inc., Nwam LLC, NN Investment Partners Holdings N.V., Capital Investment Advisors LLC and Hochman Cole Investment Advisors Inc.. View Insider Buying and Selling for iShares NASDAQ Biotechnology Index.
How do I buy shares of iShares NASDAQ Biotechnology Index?
Shares of IBB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is iShares NASDAQ Biotechnology Index's stock price today?
One share of IBB stock can currently be purchased for approximately $117.91.
How big of a company is iShares NASDAQ Biotechnology Index?
iShares NASDAQ Biotechnology Index has a market capitalization of $9.70 billion.
MarketBeat Community Rating for iShares NASDAQ Biotechnology Index (NASDAQ IBB)
MarketBeat's community ratings are surveys of what our community members think about iShares NASDAQ Biotechnology Index and other stocks. Vote "Outperform" if you believe IBB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IBB will underperform the S&P 500 over the long term. You may vote once every thirty days.
